Basiliximab - CISMeF

Preferred Label : Basiliximab;

NCIt definition : A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.;

UNII : 9927MT646M;

CAS number : 179045-86-4;

Drug name : Simulect;

Molecule name : SDZ-CHI-621;

Details

Origin ID

C52186;

UMLS CUI

C0676831;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Basiliximab [MeSH Descriptor]
- Basiliximab (substance) [SNOMED CT concept]
- Product containing basiliximab (medicinal product) [SNOMED CT concept]
- basiliximab [ATC Code]
- basiliximab [MeSH concept]
Validated automatic mappings to BTNT
- basiliximab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Interleukin-2 Receptor Subunit Alpha [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients